- Citation
- Ramurthy S, Taft BR, Aversa RJ, Barsanti PA, Burger MT, Lou Y, Nishiguchi GA, Rico A, Setti L, Smith A, Subramanian S, Tamez V, Tanner H, Wan L, Hu C, Appleton BA, Mamo M, Tandeske L, Tellew JE, Huang S, Yue Q, Chaudhary A, Tian H, Iyer R, Hassan AQ, Mathews Griner LA, La Bonte LR, Cooke VG, Van Abbema A, Merritt H, Gampa K, Feng F, Yuan J, Mishina Y, Wang Y, Haling JR, Vaziri S, Hekmat-Nejad M, Polyakov V, Zang R, Sethuraman V, Amiri P, Singh M, Sellers WR, Lees E, Shao W, Dillon MP, Stuart DD.: Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. J Med Chem, Volume 63 (5), 2020
- Authors
- Amiri P, Appleton BA, Aversa RJ, Barsanti PA, Burger MT, Chaudhary A, Cooke VG, Dillon MP, Feng F, Gampa K, Haling JR, Hassan AQ, Hekmat-Nejad M, Hu C, Huang S, Iyer R, La Bonte LR, Lees E, Lou Y, Mamo M, Mathews Griner LA, Merritt H, Mishina Y, Nishiguchi GA, Polyakov V, Ramurthy S, Rico A, Sellers WR, Sethuraman V, Setti L, Shao W, Singh M, Smith A, Stuart DD., Subramanian S, Taft BR, Tamez V, Tandeske L, Tanner H, Tellew JE, Tian H, van Abbema A, Vaziri S, Wan L, Wang Y, Yuan J, Yue Q, Zang R
- Journal
- J Med Chem
- Year
- 2020
- Machine-readable
- REST APIRDF